Clinical experiment designed to assess clinical efficacy targeting CXCL10 in human patients undergoing thoracoscopic lung cancer surgery. Primary outcome: serum CXCL10 levels and predictive accuracy for CPSP
An exploratory biomarker analysis conducted within the rTMS clinical trial to investigate the relationship between serum CXCL10 levels and chronic postsurgical pain development. CXCL10, an inflammation-related chemokine associated with chronic pain, was measured in patient sera and analyzed for its predictive accuracy for CPSP. The analysis demonstrated that patients receiving active rTMS had significantly lower CXCL10 levels compared to the sham group, and CXCL10 showed good predictive performance for identifying patients at risk of developing CPSP. This represents a potential mechanistic link between rTMS treatment effects and inflammatory processes underlying chronic pain development.
Serum CXCL10 measurement in trial participants, ROC analysis for predictive accuracy, comparison between active and sham rTMS groups
Lower CXCL10 levels in active rTMS group, good predictive accuracy for CPSP
Significant difference in CXCL10 levels between groups and AUC > 0.8 for CPSP prediction
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.